MedTrace Logo

Safety and Efficacy Study of Oral XIGO Tablets to Treat The Common Cold

NCT01092039 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2012-07-24

No results posted yet for this study

Summary

The purpose of the study will be to assess the efficacy and safety of XIGO administered orally, three times a day, compared with placebo in patients with the common cold.

Conditions

  • Common Cold

Interventions

DIETARY_SUPPLEMENT

lactoferrin, L-Glutamine and beta-glucans

Subject will be given XIGO pills or placebo. two tablets to be taken by mouth 3 times per day.

DIETARY_SUPPLEMENT

Placebo Comparator

Subject will be given placebo comparator of two tablets to be taken by mouth 3 times per day.

Sponsors & Collaborators

  • Xigo Health LLC

    lead INDUSTRY

Principal Investigators

  • Gregory G Allen J.R., D.O. · NECCR/ IMCA LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-03-31
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01092039 on ClinicalTrials.gov